Literature DB >> 12919959

Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells.

Pi-Ling Chang1, Minhton Cao, Patricia Hicks.   

Abstract

Osteopontin (OPN) is a secreted, adhesive glycoprotein. Elevated expression of OPN in malignant and benign tumors is postulated to play a role in tumorigenesis. To determine whether OPN induction is required for tumor promotion, we used the in vitro JB6 model known to correlate with tumor promotion in vivo. The skin tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induces irreversible transformation of JB6 Cl41.5a cells. Concomitantly, TPA markedly stimulates early and persistent OPN expression and secretion for at least 4 days (the time required for these cells to begin to acquire the transformed phenotype) and increases cells' adhesion to OPN. Here, we demonstrated that dexamethasone, a synthetic analog of glucocorticoid, known to inhibit tumor promotion in vivo, not only suppressed TPA-induced OPN mRNA expression and inhibited tumorigenic transformation of JB6 Cl41.5a cells (as previously shown in JB6 Cl22 and Cl41 cells), but also that the addition of OPN partially restored dexamethasone suppression of TPA-induced cell transformation. Therefore, we tested the hypothesis that OPN induction is required for tumor promoter-induced transformation of JB6 cells by examining (i) whether the addition of OPN will induce transformation, (ii) whether antisense OPN expression will inhibit TPA-induced transformation and (iii) if the latter experiment showed inhibition of TPA-induced transformation whether the addition of OPN will rescue this effect. Results indicated that the addition of purified OPN induced a dose-dependent transformation of JB6 cells, as assessed by anchorage- independent growth assay and that this induction was suppressed by antibody to OPN. Furthermore, antisense OPN expressing JB6 clones suppressed TPA-induced OPN synthesis and secretion and inhibited TPA-induced anchorage-independent growth, which was partially rescued by the addition of OPN. In conclusion, OPN induction is required and can be sufficient to induce in vitro cellular transformation of a preneoplastic murine JB6 cell line.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919959     DOI: 10.1093/carcin/bgg138

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Authors:  Xianmin Luo; Megan K Ruhland; Ermira Pazolli; Anne C Lind; Sheila A Stewart
Journal:  Mol Cancer Res       Date:  2011-06-14       Impact factor: 5.852

3.  Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.

Authors:  Chun-Ying Wu; Ming-Shiang Wu; En-Pei Chiang; Cheng-Chung Wu; Yi-Ju Chen; Chien-Jen Chen; Nai-Hui Chi; Gran-Hum Chen; Jaw-Town Lin
Journal:  Gut       Date:  2006-12-05       Impact factor: 23.059

4.  Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis.

Authors:  Corinne E Camalier; Matthew R Young; Gerd Bobe; Christine M Perella; Nancy H Colburn; George R Beck
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-09

5.  The transcriptional mediator subunit MED1/TRAP220 in stromal cells is involved in hematopoietic stem/progenitor cell support through osteopontin expression.

Authors:  Akiko Sumitomo; Ruri Ishino; Norinaga Urahama; Kana Inoue; Kenji Yonezawa; Natsumi Hasegawa; Osamu Horie; Hiroshi Matsuoka; Toru Kondo; Robert G Roeder; Mitsuhiro Ito
Journal:  Mol Cell Biol       Date:  2010-08-16       Impact factor: 4.272

6.  Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development.

Authors:  Pi-Ling Chang; Yu-Hua Hsieh; Chao-Cheng Wang; M Margaret Juliana; Yuko Tsuruta; Laura Timares; Craig Elmets; Kang-Jey Ho
Journal:  J Dermatol Sci       Date:  2014-05-21       Impact factor: 4.563

7.  Osteopontin expression in normal skin and non-melanoma skin tumors.

Authors:  Pi-Ling Chang; Louie Harkins; Yu-Hua Hsieh; Patricia Hicks; Kraisorn Sappayatosok; Somchai Yodsanga; Somporn Swasdison; Ann F Chambers; Craig A Elmets; Kang-Jey Ho
Journal:  J Histochem Cytochem       Date:  2007-10-15       Impact factor: 2.479

Review 8.  Role of osteopontin in tumour progression.

Authors:  S R Rittling; A F Chambers
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

9.  Functional characterization of stromal osteopontin in melanoma progression and metastasis.

Authors:  Santosh Kumar; Priyanka Sharma; Dhiraj Kumar; Goutam Chakraborty; Mahadeo Gorain; Gopal C Kundu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.